featured
Outcomes of First-Line Chemotherapy Plus Trastuzumab With or Without Bevacizumab for HER2/Neu-Positive MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Breast Cancer Res Treat 2024 Jul 05;[EPub Ahead of Print], J Mezzanotte-Sharpe, A ONeill, IA Mayer, CL Arteaga, XJ Yang, LI Wagner, D Cella, NJ Meropol, RK Alpaugh, TJ Saphner, RE Swaney, KL Hoelzer, WJ Gradishar, VG Abramson, PK Sundaram, SZ Jilani, EA Perez, NU Lin, M Jahanzeb, AC Wolff, GW Sledge, SA ReidFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.